ADAR2 Activators, also known as Adenosine Deaminase Acting on RNA 2 Activators, belong to a class of molecules that play a pivotal role in the regulation of RNA editing processes within living organisms. These activators are characterized by their ability to enhance the enzymatic activity of ADAR2, an enzyme that catalyzes the deamination of adenosine (A) to inosine (I) in double-stranded RNA (dsRNA) molecules. This RNA editing process is essential for fine-tuning the functional diversity of RNA transcripts, thereby influencing gene expression and protein function. ADAR2, one of the three ADAR (Adenosine Deaminase Acting on RNA) enzymes found in humans, predominantly targets neural tissues and plays a vital role in neural development and function. Activating ADAR2 can lead to increased efficiency in the deamination process, resulting in the conversion of adenosines to inosines more frequently and with greater specificity.
The mechanism of ADAR2 activation involves interactions between the activators and the enzyme's catalytic domain, ultimately enhancing its binding affinity to dsRNA substrates. This heightened binding affinity allows ADAR2 to access its target sites more effectively, leading to increased RNA editing activity. The precise structural and chemical properties of ADAR2 activators may vary, but they are generally designed to modulate the conformational changes in the enzyme's active site or stabilize its interaction with dsRNA. Understanding the mechanisms and molecular structures of these activators is crucial for elucidating the fundamental processes of RNA editing and its implications in various biological contexts, such as neural function and development. Researchers continue to investigate ADAR2 activators to gain deeper insights into their mechanisms and applications, including the development of tools for studying RNA editing and its consequences on cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
As an HDAC inhibitor, sodium butyrate may increase transcription of ADAR2 by affecting chromatin structure. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium influences several signaling pathways that could include upregulation of ADAR2 expression in the central nervous system. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $71.00 $163.00 $296.00 | 2 | |
Cholecalciferol modulates gene expression and may enhance ADAR2 expression as part of its neuroprotective roles. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
As a SIRT1 activator, resveratrol could affect ADAR2 expression through epigenetic mechanisms. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates cAMP pathways, which could lead to the upregulation of ADAR2 expression. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
As a glucocorticoid, dexamethasone can affect RNA editing mechanisms and potentially ADAR2 expression. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
DL-Sulforaphane may exert epigenetic effects that induce ADAR2 expression via antioxidant response pathways. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor may upregulate ADAR2 by demethylating its promoter region. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid is another HDAC inhibitor that might increase ADAR2 expression through epigenetic changes. | ||||||